March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
8 citations
,
July 2024 in “Children” Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
5 citations
,
December 2024 in “Anais Brasileiros de Dermatologia” Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
3 citations
,
August 2025 in “Frontiers in Pharmacology” Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
December 2022 in “Revista Medicina Cutánea Ibero-Latino-Americana” JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
Alopesi tedavisinde ilaçlar saç büyümesini teşvik eder ve yeni yaklaşımlar umut vaat eder.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
7 citations
,
January 2021 in “Dermatology and therapy” Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
6 citations
,
October 2022 in “American journal of clinical dermatology” The review shows how to properly diagnose and treat the loss of eyebrow and eyelash hair.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
1 citations
,
October 2021 in “Deleted Journal” Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.
June 2023 in “Dermatology and therapy” The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
341 citations
,
November 2009 in “The FASEB Journal” Calreticulin has roles in healing, immune response, and disease beyond its known functions in the endoplasmic reticulum.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.